ES-NK cells for hard-to-treat lupus nephritis
Part of Immune system & allergy, Kidney & urinary clinical trials.
This is an early-stage trial testing a new type of immune cell therapy (called ES-NK cells) for people with difficult-to-treat lupus nephritis—kidney inflammation caused by lupus. The goal is to see if this treatment is safe and can help calm the disease when standard medicines aren't working well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 35 years old.
- You have lupus nephritis (a kidney problem caused by lupus) that is active and confirmed by a recent kidney biopsy (Class III, IV, or combined with V).
- Your lupus is either newly diagnosed or has not responded well to standard treatments.
- You have a positive antinuclear antibody (ANA) test, and also a positive anti-dsDNA or anti-Sm antibody test.
- Your lupus disease activity score (SLEDAI-2K) is 8 or higher.
- You have significant protein in your urine (urine protein-to-creatinine ratio of 1.0 or more, or if under 18, 24-hour protein of 1.0 grams or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
Hear when a new Systemic Lupus Erythenlatosus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.